No Data
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Delivers Shareholders Notable 21% CAGR Over 3 Years, Surging 6.7% in the Last Week Alone
Yichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million
Guangdong Hec Technology Holding (01558): Guangdong Hec Pharmaceutical and Apollo company have reached an authorization licensing agreement on the development and commercialization of HEC88473 project.
hec cj pharm (01558) and the offeror guangdong hec technology holding pharmaceutical limited jointly announced the 2024 ...
Express News | YiChang HEC ChangJiang Pharmaceutical - Agreement to Develop and Commercialise Apl-18881 (Hec88473), a Fgf21 / GLP-1 Dual Receptor Agonist
Earnings Are Growing at YiChang HEC ChangJiang Pharmaceutical (HKG:1558) but Shareholders Still Don't Like Its ProspectsNo Data
No Data
